Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH

Authors

Institutions

Publication Details

Journal
Alimentary Pharmacology & Therapeutics
Published
2025-02-21
DOI
https://doi.org/10.1111/apt.70038
Citations
9
Primary Topic
Fibroblast Growth Factor Research
Type
article
Field-Weighted Citation Impact
7.25
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH

Anthony Rodgers, Ira Gantz, Keith D. Kaufman, Samuel S. Engel et al.
9 citations
Alimentary Pharmacology & Therapeutics
Fibroblast Growth Factor Research
7.25
article

Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH

Anthony Rodgers, Ira Gantz, Keith D. Kaufman, Samuel S. Engel, Annaswamy Raji, Shuai Hu, Matthew L. Rizk, Michael F. Crutchlow, Lianzhe Xu, Heather A. Flynn, Radha Krishnan
article en
9 citations

Abstract

No abstract available for this paper.
Alimentary Pharmacology & TherapeuticsVol. 61(7)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Good health and well-being
Openalex Percentile: Top 3%
Fibroblast Growth Factor Research
7.25
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.